Research programme: small-molecule nucleic acid therapeutics - Spring Bank Pharmaceuticals

Drug Profile

Research programme: small-molecule nucleic acid therapeutics - Spring Bank Pharmaceuticals

Alternative Names: Asthma and allergy therapeutics - Spring Bank; Cancer therapeutics - Spring Bank; COPD therapeutics - Spring Bank; SB 11285

Latest Information Update: 27 Oct 2016

Price : $50

At a glance

  • Originator Spring Bank Pharmaceuticals
  • Class Nucleic acids; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cytokine stimulants; Immunomodulators; Interferon stimulants; Pattern recognition receptor agonists; Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation
  • No development reported Asthma; Chronic obstructive pulmonary disease; Hypersensitivity

Most Recent Events

  • 15 Feb 2017 Spring Bank Pharmaceuticals announces intention to submit an IND application for SB 11285 to the US FDA in 2018
  • 22 Oct 2016 Early research data presented at the American Association for Cancer Research Special Conference on Tumor Immunology and Immunotherapy (AACR-2016)
  • 20 Oct 2016 Preclinical trials in Inflammation and Cancer in USA (PO) (Spring Bank Pharmaceuticals pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top